Methyl chromone compound as well as preparation method and application thereof
By developing a methylchromosterone compound, which uses its hydrogen bond complex with 3CL hydrolase to significantly inhibit its activity, it solves the problem that existing anti-SARS-CoV-2 drugs are difficult to inhibit 3CL hydrolase, and provides new Antiviral active ingredient achieves effective treatment of SARS-CoV-2.
Patent Information
- Application Number
- CN202310593557.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-24
- Publication Date
- 2024-11-26
Smart Images

Figure CN119019483A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of chemical medicines, and specifically relates to a methyl chromone compound and a preparation method and application thereof. Background Art
[0002] Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) belongs to the genus Beta virus of the subfamily Coronavirinae of the family Coronaviridae and is the main pathogen causing the novel coronavirus infection (COVID-19). The nucleic acid sequence variation of the virus may lead to antigenic drift, thereby enabling it to evade the host's immune response and affect the efficacy of the vaccine.
[0003] 3CL hydrolase is an enzyme necessary for SARS-CoV-2 replication. It is used to hydrolyze the polyproteins pp1a and pp1ab of SARS-CoV-2 to produce non-structural proteins involved in transcription and viral replication. If the activity of 3CL hydrolase can be inhibited, the self-replication and reproduction of the virus can be blocked, thereby achieving the therapeutic purpose. In addition, 3CL hydrolase has no human homologous genes and is a relatively safe drug target. Therefore, drugs that act on this target have good application prospects, and obtaining more compounds that can be used to inhibit the activity of 3CL hydrolase is of great significance for the development of anti-SARS-CoV-2 drugs and the treatment of diseases caused by it. Summary of the invention
[0004] In view of the above problems, the present invention provides a methyl chromone compound and a preparation method and application thereof. The compound can stably bind to the 3CL hydrolase target and has a very significant inhibitory activity on 3CL hydrolase, thereby exerting an excellent antiviral effect.
[0005] In order to achieve the above-mentioned purpose of the invention, the embodiment of the present invention adopts the following technical solutions:
[0006] In a first aspect, the present invention provides a methyl chromone compound, the structural formula of which is shown in Formula I:
[0007]
[0008] Molecular dynamics simulation shows that the above-mentioned methyl chromone compound provided by the present invention can form a stable complex with 3CL hydrolase through hydrogen bonding, and the structure of the sugar ring in the compound and the amino acid residue Thr190 play an important role in the formation of hydrogen bonding. The stability of the complex is comparable to other drugs that currently work by inhibiting 3CL hydrolase. In addition, the compound can form a stable interaction with the binding pocket of 3CL hydrolase and stabilize the amino acid residues therein. Activity evaluation experiments have found that the inhibitory activity of the compound for 3CL hydrolase is more prominent than other compounds with similar structures.
[0009] Therefore, the methyl chromone compound provided by the present invention can be used to prepare anti-SARS-CoV-2 drugs. The compound is a new compound that has not been reported yet, and provides a new active ingredient for the design of anti-SARS-CoV-2 drugs.
[0010] In a second aspect, the present invention also provides a method for preparing the above-mentioned methyl chromone compound, comprising the following steps:
[0011] Step A, extracting the Rhizoma Cynomorii with water, adding ethanol to the obtained water extract, separating the supernatant after static precipitation, removing alcohol from the supernatant, extracting with ethyl acetate and n-butanol, and collecting the aqueous phase;
[0012] Step B, separating the aqueous phase by column chromatography using a macroporous resin column: eluting with water and 5-95% v / v ethanol in sequence, collecting the eluate obtained by eluting with 5-95% v / v ethanol, and concentrating it into a dry paste to obtain a first dry paste;
[0013] Step C, dissolving the first dry paste with an organic solvent, and separating it by column chromatography using a silica gel column: eluting with ethyl acetate, ethanol or a mixture of the two, collecting the obtained eluate, and concentrating it into a dry paste to obtain a second dry paste;
[0014] Step D: Separate the second dry paste using reverse medium pressure preparative chromatography using reverse phase silica gel: elute with 5-15% v / v methanol, 20-30% v / v methanol, and 35-50% v / v methanol in sequence, collect the eluate obtained by eluting with 35-50% v / v methanol, and concentrate to obtain a crude extract containing the methyl chromone compound.
[0015] The invention can obtain a crude extract containing the methyl chromone compound by extracting the radix cyrtonemae with water and precipitating it with alcohol, extracting it with ethyl acetate and n-butanol, and then gradually separating the extract with the above separation process.
[0016] In combination with the first aspect, in steps B, C, and D, the amount of each eluent used can be selected to be 1 to 10 column volumes.
[0017] In combination with the first aspect, the concentration of ethanol in step B is preferably 20% v / v. When elution is performed with ethanol at this concentration, the amount of the eluent used can be 5 column volumes.
[0018] In combination with the first aspect, in step B, the macroporous resin in the macroporous resin column may be AB-8 resin.
[0019] In combination with the first aspect, the organic solvent used to dissolve the first dry paste in step C can be selected from methanol, dichloromethane or a mixture of the two. After the first dry paste is dissolved in the organic solvent, it is mixed with 200-300 mesh silica gel at a mass ratio of 1:3-1, and then the solvent is evaporated to dryness, and added to a silica gel column filled with 200-300 mesh silica gel (equivalent to 5-50 times the weight of the dry paste), and column chromatography separation can be performed.
[0020] In combination with the first aspect, step C preferably uses ethyl acetate for elution, then ethyl acetate-ethanol with a volume ratio of 9:1, and then ethyl acetate-ethanol with a volume ratio of 8:2, and the eluate obtained by eluting with ethyl acetate-ethanol with a volume ratio of 8:2 is collected and concentrated into a dry paste to obtain a second dry paste. When eluting with this operation, the amount of ethyl acetate and ethyl acetate-ethanol can be selected to be 5 column volumes.
[0021] In combination with the first aspect, the preparation method further comprises dissolving the crude extract with a methanol aqueous solution, separating by semi-preparative high performance liquid chromatography, wherein the mobile phase of the semi-preparative high performance liquid chromatography is 5% to 95% v / v acetonitrile aqueous solution-0 to 0.5% v / v formic acid aqueous solution in a volume ratio of 1.5:8.5, and isocratic elution. The eluted fractions are collected according to the peak time of the compound to obtain the compound monomer.
[0022] The concentration of the methanol aqueous solution for dissolving the crude extract is not limited, as long as it can dissolve the crude extract. Exemplarily, the concentration of the methanol aqueous solution is 45-55% v / v.
[0023] Preferably, the chromatographic column of the semi-preparative high performance liquid chromatography is octadecyl bonded silica gel, preferably YMC-Pack R&D ODS-A, with specifications of 250×20 mm, S-10 μm.
[0024] Preferably, the column temperature of the semi-preparative HPLC is 25-35°C, more preferably 30°C.
[0025] Preferably, the flow rate of the semi-preparative HPLC method is 1.5 to 2.5 mL / min, more preferably 2 mL / min.
[0026] In a third aspect, the present invention also provides the use of the above-mentioned methyl chromone compound in the preparation of 3CL hydrolase inhibitors.
[0027] In a fourth aspect, the present invention also provides the use of the above-mentioned methyl chromone compound in the preparation of anti-coronavirus drugs.
[0028] Experimental verification showed that the compound can stably bind to 3CL hydrolase and has outstanding inhibitory activity against 3CL hydrolase, and can produce excellent anti-coronavirus effects, so it can be used to prepare anti-coronavirus drugs.
[0029] In combination with the fourth aspect, the anti-coronavirus drug is an anti-severe acute respiratory syndrome coronavirus type 2 virus drug. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figure 1 is the IR spectrum of compound A in Example 1 of the present invention;
[0031] Figure 2 is the HR-ESI-MS spectrum of compound A in Example 1 of the present invention;
[0032] Figure 3 is the compound A in Example 1 of the present invention 1 H--NMR spectrum;
[0033] Figure 4 is the compound A in Example 1 of the present invention 13 C-NMR spectrum;
[0034] Figure 5 is the HSQC spectrum of compound A in Example 1 of the present invention;
[0035] Figure 6 is the HMBC spectrum of compound A in Example 1 of the present invention;
[0036] Figure 7 is the structure and key HMBC of compound A in Example 1 of the present invention;
[0037] Figure 8 is the fluctuation of the root mean square fluctuation (RMSF) value of the amino backbone atoms in the compound A-protein complex in Example 6 of the present invention;
[0038] Fig. 9 This is the last conformation of the complex of compound A and 3CL hydrolase in Example 6 of the present invention after stabilization for 100 nanoseconds in molecular dynamics simulation. DETAILED DESCRIPTION
[0039] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with specific embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.
[0040] SARS-CoV-2 is the main pathogen that causes COVID-19. The nucleic acid sequence variation of the virus may lead to antigenic drift, thereby allowing the virus to evade the host's immune response and affect the efficacy of the vaccine. The embodiment of the present invention provides a methyl chromone compound (5,7-dihydroxy-2-methyl chromone-7-O-β-D-glucuronic acid), the structural formula of which is shown in Formula I:
[0041]
[0042] 3CL hydrolase plays a key role in the replication of SARS-CoV-2 and can be used as an important target for screening antiviral drugs. Molecular docking results show that the compound can form a stable complex with 3CL hydrolase; molecular dynamics studies have shown that the compound can form a stable interaction with the binding pocket of 3CL hydrolase and stabilize the amino acid residues therein; activity evaluation experiments have shown that compared with other compounds with similar structures, the compound has more prominent inhibitory activity against 3CL hydrolase. Therefore, the compound can play a good role in anti-SARS-CoV-2 and can become a new active ingredient for antiviral drugs.
[0043] The present invention also provides a method for preparing the compound, comprising the following steps:
[0044] Step A, extracting the Rhizoma Cynomorii with water, adding ethanol to the obtained water extract, separating the supernatant after static precipitation, removing alcohol from the supernatant, extracting with ethyl acetate and n-butanol, and collecting the aqueous phase;
[0045] Step B, separating the aqueous phase by column chromatography using a macroporous resin column: eluting with water and 5-95% v / v ethanol in sequence, collecting the eluate obtained by eluting with 5-95% v / v ethanol, and concentrating it into a dry paste to obtain a first dry paste;
[0046] Step C, dissolving the first dry paste with an organic solvent, and separating it by column chromatography using a silica gel column: eluting with ethyl acetate, ethanol or a mixture of the two, collecting the obtained eluate, and concentrating it into a dry paste to obtain a second dry paste;
[0047] Step D: Separate the second dry paste using reverse medium pressure preparative chromatography using reverse phase silica gel: elute with 5-15% v / v methanol, 20-30% v / v methanol, and 35-50% v / v methanol in sequence, collect the eluate obtained by eluting with 35-50% v / v methanol, and concentrate to obtain a crude extract containing the above-mentioned methyl chromone compound.
[0048] In the above preparation method, the crude extract obtained in step D is dissolved in methanol aqueous solution and separated by semi-preparative high performance liquid chromatography to obtain the compound monomer. The mobile phase preferably uses a 5% to 95% v / v acetonitrile aqueous solution-0 to 0.5% v / v formic acid aqueous solution in a volume ratio of 1.5:8.5, and the eluted fraction is collected according to the peak time of the compound. The chromatographic column preferably uses octadecyl bonded silica gel, such as YMC-Pack R&D ODS-A (250×20mm, S-10μm). The column temperature is preferably 25 to 35°C. The flow rate is preferably 1.5 to 2.5mL / min.
[0049] In order to obtain a better separation effect and reduce the loss of the target product at the same time, the concentration of ethanol in step B is preferably 20% v / v, and step C is preferably eluted with ethyl acetate first, then eluted with ethyl acetate-ethanol with a volume ratio of 9:1, and then eluted with ethyl acetate-ethanol with a volume ratio of 8:2, and the eluate obtained by eluting with ethyl acetate-ethanol with a volume ratio of 8:2 is collected.
[0050] The scheme of the present invention is described below through specific embodiments.
[0051] Example 1
[0052] This embodiment provides a methyl chromone compound 5,7-dihydroxy-2-methyl chromone-7-O-β-D-glucuronic acid (hereinafter referred to as compound A) and a preparation method thereof.
[0053] The preparation method of compound A specifically comprises the following steps:
[0054] 1. Preparation of crude extract
[0055] Step A, add 450L of water to 45kg of Mianma Guanzhong and reflux extract for 3 times, each time for 1 hour. Combine the extracts, concentrate under reduced pressure to a specific gravity of 1.10-1.20, add ethanol to a mass concentration of 80%, stand at 4℃ for 24 hours, filter, and take the supernatant. Concentrate the supernatant under reduced pressure until there is no alcohol taste, add water to make the volume 20L, extract with equal volumes of ethyl acetate and n-butanol three times respectively, and then take the aqueous solution;
[0056] Step B, the aqueous solution was fixed to 180 L, and separated using an AB-8 resin column (resin dosage 90 kg), and the separation process was as follows: washing with 5 BV of water and eluting with 20% v / v ethanol, collecting the 20% v / v ethanol eluate (5 BV), and removing the solvent under reduced pressure to obtain a dry paste (first dry paste);
[0057] Step C. Separate the first dry paste obtained in step B using a silica gel (200-300 mesh) column. The separation process is as follows: dissolve the first dry paste in methanol, mix it with silica gel in a mass ratio of 1:2, then evaporate the solvent to dryness, add it to a silica gel column filled with silica gel (equivalent to 20 times the weight of the dry paste), first elute with 5BV ethyl acetate, then elute with 5BV ethyl acetate-ethanol (9:1, v / v), and then elute with 5BV ethyl acetate-ethanol (8:2, v / v), collect the ethyl acetate-ethanol (8:2, v / v) eluate, remove the solvent under reduced pressure, and obtain a dry paste (the second dry paste).
[0058] Step D: Dissolve the second dry paste obtained in step C with methanol, add an equal amount of reversed-phase silica gel (YMC GEL, ODS-AQ-HG, S-50 μm) and mix the sample. After evaporating the solvent, separate the sample by reversed-phase medium-pressure preparative chromatography (filler: YMC GEL, ODS-AQ-HG, S-50 μm; chromatographic column specification: 49×460 mm), and elute with 10% v / v methanol for 5VB, 25% v / v methanol for 5BV, and 40% v / v methanol for 5BV in sequence. Collect the 40% v / v methanol eluate, and remove the solvent under reduced pressure to obtain a crude extract.
[0059] 2. Monomer preparation
[0060] The crude extract was dissolved in 50% v / v methanol aqueous solution, filtered and injected into Waters 1525 semi-preparative liquid chromatograph. The chromatographic conditions were:
[0061] Chromatographic column model: YMC-Pack R&D ODS-A (250×20mm, S-10μm); mobile phase is 50% v / v ACN aqueous solution-0.2% v / v formic acid aqueous solution (1.5:8.5); flow rate 2mL / min; detection wavelength: 210nm, 240nm; column temperature: 30℃; injection volume: 20μl. The results show that under this chromatographic condition, the chromatographic peak separation is good and can be used for preparation and purification. The peak with a retention time of about 25min (the collection time in this embodiment is 24-26min) was collected, and the solvent was recovered under reduced pressure to obtain 35mg of compound A with a purity of >98%.
[0062] 3. Structural identification of compound A
[0063] The chemical structure of compound A was characterized by infrared spectroscopy (IR), mass spectroscopy (MS) and nuclear magnetic resonance (NMR).
[0064] The test data are as follows: IR (KBr) λ max :3303, 2907, 1723, 1622, 1502, 1423, 1336, 1259, 1176, 1079, 939, 823, 761, 682, 559cm -1;HR-TOF / MS: m / z 369.0814[M+H] + (The calculated value is 369.0822); 1 H-NMR (600 MHz, DMSO-d 4 )and 13 C-NMR (150 MHz, DMSO-d 4 ) data are shown in Table 1. 1 H-NMR and 13 The C-NMR signals were completely assigned by a combination of HSQC and HMBC.
[0065] IR spectrum, HR-ESI-MS spectrum, 1 H--NMR spectrum, 13 The C-NMR spectrum, HSQC spectrum and HMBC spectrum are shown in Figure 1 to Figure 6 shown.
[0066] Table 1 Compound A in 1 H-NMR and 13 C-NMR spectral data (DMSO-d 6 )
[0067]
[0068] 4. Experimental Results
[0069] The obtained compound A is a colorless powder, and its molecular formula is C 16 H 16 O 10 . Infrared spectra show that hydroxyl (3303cm -1 ) and carbonyl (1622cm -1 ) characteristic bands. The NMR spectrum (Table 1) shows that in δ H There is an anomeric proton at 5.24 (1H, d, J = 7.4 Hz, H-1', with δ C 99.4), in δ H There is a methyl group at 2.39 (3H, s, H-11, with δ C 20.1), there is a hydroxyl proton (OH, brs, C-5) at ΔH.12.83, and at δ H 6.43 (1H, d, J = 1.7 Hz, H-6, and δ C 99.2) and 6.69 (1H, brs, H-8, and δ C 94.4) at the meta-coupled aromatic protons. C161.3 (C-5), 99.2 (C-6), 162.5 (C-7), 94.4 (C-8), 157.5 (C-9), 105.3 (C-10) and δ C 168.5(C-2), 108.4(C-3) 13 The C-NMR carbon signal also indicates the presence of an aromatic ring fragment and a pair of olefinic fragments. 13 In the C-NMR spectrum, at δ C There is a keto carbonyl group at 182.1 (C-4) and at δ C There is a carboxyl group at 170.2 (C-6'). Combined with the unsaturation analysis, the unsaturation of compound A is 9. Among them, the two carbonyl groups are two unsaturated, the glucose group is one unsaturated; the benzene ring structure is four unsaturated; it is speculated that there is another ring structure in the structure of compound A. The structure was further studied by two-dimensional nuclear magnetic resonance spectroscopy. δ H 6.25(H-3) and δ C The HMBC correlation between 168.5 (C-2) and 182.1 (C-4) indicated that the aglycone of compound A was a benzopyran (4-chromone) structure.
[0070] The compound A was hydrolyzed with 5% HCl to obtain a mixture of aglycone and sugar. The sugar in the mixture was further purified by EtOAc extraction to remove the aglycone. After concentration, the sugar was identified by TLC (Merck Silica gel 60F254) compared with real D-glucuronic acid, and the solvent system was EtOAc-MeOH-H 2 O-AcOH (10:10:5:0.5), the developer is 10% sulfuric acid ethanol solution. It was identified that the compound A was hydrolyzed to produce D-glucuronic acid. The J value at C-1′ determined that the configuration of the anomeric carbon of the glucosyl fragment was β. H 5.24(H-1′) and δ C The HMBC correlation between 162.5 (C-7) and 162.5 (C-7) determined the position of the glucopyranosyl fragment attached to C-7 of the aglycone; H 2.39(H-11) and δ C 168.5(C-2),δ H 2.39H-11 and δ C The position of the methyl group attached to C-2 was determined by HMBC correlation between 108.4 (C-3).
[0071] Based on these observations, the structure of compound A was identified as 5,7-dihydroxy-2-methylchromone-7-O-β-D-glucuronide (structure and key HMBC as Figure 7 shown).
[0072] Example 2
[0073] This embodiment provides a methyl chromone compound 5,7-dihydroxy-2-methyl chromone-7-O-β-D-glucuronic acid (ie, compound A) and a preparation method thereof.
[0074] The preparation method of compound A specifically comprises the following steps:
[0075] 1. Preparation of crude extract
[0076] Step A, add 450L of water to 45kg of Mianma Guanzhong and reflux extract for 3 times, each time for 1 hour. Combine the extracts, concentrate under reduced pressure to a specific gravity of 1.10-1.20, add ethanol to a mass concentration of 80%, stand at 4℃ for 24 hours, filter, and take the supernatant. Concentrate the supernatant under reduced pressure until there is no alcohol taste, add water to make the volume 20L, extract with equal volumes of ethyl acetate and n-butanol three times respectively, and then take the aqueous solution;
[0077] Step B, the aqueous solution was fixed to 180 L, and separated using an AB-8 resin column (resin dosage 90 kg), and the separation process was as follows: washing with 5 BV of water and eluting with 35% v / v ethanol, collecting the 35% v / v ethanol eluate (4 BV), and removing the solvent under reduced pressure to obtain a dry paste (first dry paste);
[0078] Step C. Separate the first dry paste obtained in step B using a silica gel (200-300 mesh) column. The separation process is as follows: dissolve the first dry paste in methanol, mix it with silica gel in a mass ratio of 1:1.5, evaporate the solvent to dryness, add it to a silica gel column filled with silica gel (equivalent to 15 times the weight of the dry paste), first elute with 5BV of ethyl acetate, then elute with 5BV of ethanol, collect the ethanol eluate, remove the solvent under reduced pressure, and obtain a dry paste (the second dry paste).
[0079] Step D: Dissolve the second dry paste obtained in step C with methanol, add an equal amount of reversed-phase silica gel (YMC GEL, ODS-AQ-HG, S-50 μm) and mix the sample. After evaporating the solvent, separate the sample by reversed-phase medium-pressure preparative chromatography (filler: YMC GEL, ODS-AQ-HG, S-50 μm; chromatographic column specification: 49×460 mm), and elute with 5% v / v methanol 7VB, 25% v / v methanol 5BV, and 45% v / v methanol 5BV in sequence. Collect the 45% v / v methanol eluate, and remove the solvent under reduced pressure to obtain a crude extract.
[0080] 2. Monomer preparation
[0081] The crude extract was dissolved in 45% v / v methanol aqueous solution, filtered and injected into Waters 1525 semi-preparative liquid chromatograph. The chromatographic conditions were:
[0082] Chromatographic column model: YMC-Pack R&D ODS-A (250×20mm, S-10μm); mobile phase is 45% v / v ACN aqueous solution-0.1% v / v formic acid aqueous solution (1.5:8.5); flow rate 2mL / min; detection wavelength: 210nm, 240nm; column temperature: 30℃; injection volume: 20μl. The results show that under this chromatographic condition, the chromatographic peak separation is good and can be used for preparation and purification. The eluent was collected at the peak time of compound A, and the solvent was recovered under reduced pressure to obtain 17mg of compound A with a purity of >98%.
[0083] Example 3
[0084] This embodiment provides a methyl chromone compound 5,7-dihydroxy-2-methyl chromone-7-O-β-D-glucuronic acid (ie, compound A) and a preparation method thereof.
[0085] The preparation method of compound A specifically comprises the following steps:
[0086] 1. Preparation of crude extract
[0087] Step A, add 450L of water to 45kg of Mianma Guanzhong and reflux extract for 3 times, each time for 1 hour. Combine the extracts, concentrate under reduced pressure to a specific gravity of 1.10-1.20, add ethanol to a mass concentration of 80%, stand at 4℃ for 24 hours, filter, and take the supernatant. Concentrate the supernatant under reduced pressure until there is no alcohol taste, add water to make the volume 20L, extract with equal volumes of ethyl acetate and n-butanol three times respectively, and then take the aqueous solution;
[0088] Step B, the aqueous solution was fixed to 180 L, and separated using an AB-8 resin column (resin dosage 90 kg), and the separation process was as follows: washing with 5 BV of water and eluting with 65% v / v ethanol, collecting the 65% v / v ethanol eluate (7 BV), and removing the solvent under reduced pressure to obtain a dry paste (first dry paste);
[0089] Step C. Separate the first dry paste obtained in step B using a silica gel (200-300 mesh) column. The separation process is as follows: dissolve the first dry paste in methanol, mix it with silica gel in a mass ratio of 1:2.5, evaporate the solvent to dryness, add it to a silica gel column filled with silica gel (equivalent to 35 times the weight of the dry paste), first elute with 5BV of ethyl acetate, then elute with 6BV of ethyl acetate-ethanol (7:3, v / v), collect the ethyl acetate-ethanol (7:3, v / v) eluate, remove the solvent under reduced pressure, and obtain a dry paste (the second dry paste).
[0090] Step D: Dissolve the second dry paste obtained in step C with methanol, add an equal amount of reversed-phase silica gel (YMC GEL, ODS-AQ-HG, S-50 μm) and mix the sample. After evaporating the solvent, separate the sample by reversed-phase medium-pressure preparative chromatography (filler: YMC GEL, ODS-AQ-HG, S-50 μm; chromatographic column specification: 49×460 mm), and elute with 15% v / v methanol 5VB, 20% v / v methanol 5BV, and 40% v / v methanol 5BV in sequence. Collect the 40% v / v methanol eluate, and remove the solvent under reduced pressure to obtain a crude extract.
[0091] 2. Monomer preparation
[0092] The crude extract was dissolved in 55% v / v methanol aqueous solution, filtered and injected into Waters 1525 semi-preparative liquid chromatograph. The chromatographic conditions were:
[0093] Chromatographic column model: YMC-Pack R&D ODS-A (250×20mm, S-10μm); mobile phase is 35% v / v ACN aqueous solution-0.3% v / v formic acid aqueous solution (1.5:8.5); flow rate 2mL / min; detection wavelength: 210nm, 240nm; column temperature: 30℃; injection volume: 20μl. The results show that under this chromatographic condition, the chromatographic peak separation is good and can be used for preparation and purification. The eluent was collected at the peak time of compound A, and the solvent was recovered under reduced pressure to obtain 15mg of compound A with a purity of >98%.
[0094] Example 4
[0095] This embodiment provides a methyl chromone compound 5,7-dihydroxy-2-methyl chromone-7-O-β-D-glucuronic acid (ie, compound A) and a preparation method thereof.
[0096] The preparation method of compound A specifically comprises the following steps:
[0097] 1. Preparation of crude extract
[0098] Step A: 45 kg of Rhizoma Cynomorii is added with 400 L of water and refluxed for extraction 3 times, each time for 1 hour. Combine the extracts, concentrate under reduced pressure to a specific gravity of 1.10-1.20, add ethanol to a mass concentration of 80%, stand at 4°C for 24 hours, filter, and take the supernatant. The supernatant is concentrated under reduced pressure until there is no alcohol taste, add water to make the volume 20 L, extract with equal volumes of ethyl acetate and n-butanol three times respectively, and then take the aqueous solution;
[0099] Step B, the aqueous solution was fixed to 160 L, and separated using an AB-8 resin column (resin dosage 90 kg), and the separation process was as follows: washing with 5 BV of water and eluting with 5% v / v ethanol, collecting 5% v / v ethanol eluate (10 BV), and removing the solvent under reduced pressure to obtain a dry paste (first dry paste);
[0100] Step C. Separate the first dry paste obtained in step B using a silica gel (200-300 mesh) column. The separation process is as follows: dissolve the first dry paste in dichloromethane, mix it with silica gel in a mass ratio of 1:1, and then evaporate the solvent to dryness. Add it to a silica gel column filled with silica gel (equivalent to 5 times the weight of the dry paste), elute with 2BV ethyl acetate, collect the eluate, and remove the solvent under reduced pressure to obtain a dry paste (the second dry paste).
[0101] Step D: Dissolve the second dry paste obtained in step C with methanol, add an equal amount of reversed-phase silica gel (YMC GEL, ODS-AQ-HG, S-50 μm) and mix the sample. After evaporating the solvent, separate the sample by reversed-phase medium-pressure preparative chromatography (filler: YMC GEL, ODS-AQ-HG, S-50 μm; chromatographic column specification: 49×460 mm), and elute with 5% v / v methanol 7VB, 20% v / v methanol 9BV, and 35% v / v methanol 9BV in sequence. Collect the 35% v / v methanol eluate, and remove the solvent under reduced pressure to obtain a crude extract.
[0102] 2. Monomer preparation
[0103] The crude extract was dissolved in 35% v / v methanol aqueous solution, filtered and injected into Waters 1525 semi-preparative liquid chromatograph. The chromatographic conditions were:
[0104] Chromatographic column model: YMC-Pack R&D ODS-A (250×20mm, S-10μm); mobile phase is 5% v / v ACN aqueous solution-water (1.5:8.5); flow rate 2mL / min; detection wavelength: 210nm, 240nm; column temperature: 30℃; injection volume: 20μl. The results show that under this chromatographic condition, the chromatographic peak separation is good and can be used for preparation and purification. The eluent was collected at the peak time of compound A, and the solvent was recovered under reduced pressure to obtain 12mg of compound A with a purity of >98%.
[0105] Example 5
[0106] This embodiment provides a methyl chromone compound 5,7-dihydroxy-2-methyl chromone-7-O-β-D-glucuronic acid (ie, compound A) and a preparation method thereof.
[0107] Step A, add 450L of water to 45kg of Mianma Guanzhong and reflux extract for 3 times, each time for 1 hour. Combine the extracts, concentrate under reduced pressure to a specific gravity of 1.10-1.20, add ethanol to a mass concentration of 85%, stand at 4℃ for 24 hours, filter, and take the supernatant. Concentrate the supernatant under reduced pressure until there is no alcohol taste, add water to make the volume 20L, extract with equal volumes of ethyl acetate and n-butanol three times respectively, and then take the aqueous solution;
[0108] Step B, the aqueous solution was fixed to 180L, and separated using an AB-8 resin column (resin dosage 90kg), and the separation process was as follows: washing with 5BV of water and eluting with 95% v / v ethanol, collecting 95% v / v ethanol eluate (1BV), and removing the solvent under reduced pressure to obtain a dry paste (first dry paste);
[0109] Step C. Separate the first dry paste obtained in step B using a silica gel (200-300 mesh) column. The separation process is as follows: dissolve the first dry paste with methanol-dichloromethane (1:1, v / v), mix it with silica gel in a mass ratio of 1:3, and then evaporate the solvent to dryness, add it to a silica gel column filled with silica gel (equivalent to 50 times the weight of the dry paste), elute with 10BV ethanol, collect the eluate, and remove the solvent under reduced pressure to obtain a dry paste (the second dry paste).
[0110] Step D: Dissolve the second dry paste obtained in step C with methanol, add an equal amount of reversed-phase silica gel (YMC GEL, ODS-AQ-HG, S-50 μm) and mix the sample. After evaporating the solvent, separate the sample by reversed-phase medium-pressure preparative chromatography (filler: YMC GEL, ODS-AQ-HG, S-50 μm; chromatographic column specification: 49×460 mm), and elute with 15% v / v methanol for 3VB, 30% v / v methanol for 4BV, and 50% v / v methanol for 4BV in sequence. Collect the 50% v / v methanol eluate, and remove the solvent under reduced pressure to obtain a crude extract.
[0111] 2. Monomer preparation
[0112] The crude extract was dissolved in 70% v / v methanol aqueous solution, filtered and injected into Waters 1525 semi-preparative liquid chromatograph. The chromatographic conditions were:
[0113] Chromatographic column model: YMC-Pack R&D ODS-A (250×20mm, S-10μm); mobile phase is 95% v / v ACN aqueous solution-0.5% v / v formic acid aqueous solution (1.5:8.5); flow rate 2mL / min; detection wavelength: 210nm, 240nm; column temperature: 30℃; injection volume: 20μl. The results show that under this chromatographic condition, the chromatographic peak separation is good and can be used for preparation and purification. The eluent was collected at the peak time of compound A, and the solvent was recovered under reduced pressure to obtain 11mg of compound A with a purity of >98%.
[0114] Example 6
[0115] In this example, the binding and activity of compound A obtained in Example 1 with 3CL hydrolase were evaluated.
[0116] 1. Activity prediction
[0117] The SDF file of compound A was downloaded from the PubChem database (https: / / pubchem.ncbi.nlm.nih.gov / ) and converted to MOL2 format by Open Babel 2.4.1. The crystal structure of the novel coronavirus (SARS-CoV-2) 3CL hydrolase (PDBID: 7VH8) was downloaded from the PDB database (https: / / www.rcsb.org / ). In addition to the co-crystallized ligand PF-07321332 (nirmatrelvir), three drugs (α-ketoamide, lopinavir, and ritonavir) that have been reported to inhibit 3CL hydrolases were selected as positive controls. The small molecules were energy minimized using PyRx-0.8 software. Ligands and receptors were prepared according to the AutoDock Vina1.1.2 tutorial. For each structure, water molecules were removed, nonpolar hydrogens were added, Gasteiger charges were calculated, and saved in PDBQT format. Generally, the lower the Vina score, the higher the affinity between the ligand and the receptor. The general selection threshold is a binding energy ≤ -5 kcal / mol.Finally, the interaction pattern between compound A and 3CL hydrolase was visualized using Pymol software.
[0118] This example also tests the binding affinity of two other self-isolated compounds b and c that are similar in structure to compound A to 3CL hydrolase.
[0119] The results are shown in Table 2.
[0120] Table 2 Docking scores between each compound and 3CL hydrolase
[0121]
[0122] The binding free energies of the above compounds with the 3CL hydrolase target are all lower than -5.0 kJ / mol (a binding free energy less than -5 kcal / mol is considered to have good binding activity. The lower the binding energy, the more stable the ligand-receptor binding conformation), indicating that the ligand and receptor can bind stably.
[0123] In order to dynamically analyze the interaction mode between the receptor 3CL hydrolase and compound A from the perspective of kinetics and thermodynamics, molecular dynamics simulation was performed using GROMACS 4.5 in this example. Protein topology parameters were obtained from the CHARMM36 force field using the PDB2GMX tool. The electrostatic potential of the inhibitor atomic charge was calculated using the Def2-MTZVP basis set of ORCA, and the RESP charge was obtained by fitting using the program Multiwfn 3.7. The complex was placed in a The dodecahedral TIP3P water box was filled with Na + and Cl - To maintain electroneutrality, energy minimization and pre-equilibration were performed. Finally, molecular dynamics simulations were performed at 300 K for 100 ns with a time interval of 2 fs, and energy and coordinate files were saved every 10 ps.
[0124] The results showed that after 35ns of simulation, the root mean square deviation (RMSD) of all systems was 0.1-0.3nm, the fluctuation range was below 0.1nm, and all reached equilibrium.
[0125] By calculating the root mean square fluctuation (RMSF) of the amino backbone atoms in the molecular dynamics simulation of the small molecule and the receptor protein in the complex, this experiment analyzed the effect of compound A on the fluctuation of each amino acid residue in 3CL hydrolase. The study found that the distribution trend of the RMSF value of the complex formed by compound A and 3CL hydrolase obtained in Example 1 is similar to that of PF-07321332 (e.g. Figure 8 The results show that compound A can form a stable interaction with the binding pocket of 3CL hydrolase and stabilize the amino acid residues therein.
[0126] This experiment extracted the last conformation of the complex after stabilization for 100 nanoseconds in molecular dynamics simulation (e.g. Fig. 9As shown). In order to explore the important role of key groups or amino acid residues in the molecule in the formation of hydrogen bonds, this experiment summarizes the amino acid residues that form hydrogen bonds between 3CL hydrolase and compound A and compound c, as shown in Table 3. The results show that the interaction between 3CL hydrolase and the co-crystallized molecule PF-07321332 includes not only hydrogen bonds, but also CH bonds, halogen bonds and alkyl bonds. The interaction between the compound and the amino acid residue is mainly hydrogen bonding. The force of hydrogen bonding reduces the binding energy and increases the affinity. Compound A tightly binds to the active site of 3CL hydrolase to form a stable complex, which can effectively prevent the attachment of foreign viruses and the invasion of host cells.
[0127] PF-07321332 formed three hydrogen bonds with the amino acid residues (Asn142, Glu166 and Gln192) of 3CL hydrolase, indicating that these three amino acid residues may be very important in the drug action process. Compared with the cocrystallized molecule PF-07321332, the sugar ring structure in compound A and compound c played a key role in the formation of hydrogen bonds. Glu166 participated in the formation of hydrogen bonds in the stable conformation of compound A, compound c and 3CL hydrolase. This experiment also found two new amino acid residues, Thr190 and Arg188, the former played a key role in the formation of stable conformation of compound A and compound c with 3CL hydrolase, and the latter played a key role in the formation of stable conformation of compound c with 3CL hydrolase, indicating that they may also play an important role in the action of antiviral drugs.
[0128] Table 3 Hydrogen bonds between compounds and 3CL hydrolase
[0129]
[0130] 2. Activity evaluation
[0131] 50 μL of compound A, compound B, and compound C stock solutions (all 100 mM) were added to a 384-well plate, and then DMSO was added to dilute the solutions into a series of concentrations, with a total of 10 concentrations. 665SYSTEMLABCYTE) Transfer 0.2μL of the diluted solution to a 384-well assay plate, with 2 replicates for each sample. Add 10μL of 3CL hydrolase (BPSbioscience) working solution to a 384-well plate, centrifuge at 1000prm for 1 minute, and incubate at 25°C for 15min. Add 10μL of substrate working solution and incubate at 25°C for 4h. Measure the Ex 350nm and Em 460nm fluorescence signals with an ELISA reader. Calculate the enzyme activity inhibition rate according to the following formula.
[0132] Inhibition percentage of compound (%inh) = 100 × (ave high control - cpd (compound) well) / (ave high control - ave low control)
[0133] The results are shown in Table 4.
[0134] Table 4 Activity test results
[0135]
[0136]
[0137] Example 7
[0138] This embodiment provides an anti-severe acute respiratory syndrome coronavirus type 2 virus drug, the active ingredient of the drug is 5,7-dihydroxy-2-methylchromone-7-O-β-D-glucuronic acid obtained in Example 1.
[0139] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modification, equivalent substitution or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. A methyl chromone compound, It is characterized in that Its structural formula is shown in Formula I:
2. A method for preparing the methyl chromone compound according to claim 1, It is characterized in that The following steps are involved: Step A, extracting the Rhizoma Cynomorii with water, adding ethanol to the obtained water extract, separating the supernatant after static precipitation, removing alcohol from the supernatant, extracting with ethyl acetate and n-butanol, and collecting the aqueous phase; Step B, separating the aqueous phase by column chromatography using a macroporous resin column: eluting with water and 5-95% v / v ethanol in sequence, collecting the eluate obtained by eluting with 5-95% v / v ethanol, and concentrating it into a dry paste to obtain a first dry paste; Step C, dissolving the first dry paste with an organic solvent, and separating it by column chromatography using a silica gel column: eluting with ethyl acetate, ethanol or a mixture of the two, collecting the obtained eluate, and concentrating it into a dry paste to obtain a second dry paste; Step D: Separate the second dry paste using reverse medium pressure preparative chromatography using reverse phase silica gel: elute with 5-15% v / v methanol, 20-30% v / v methanol, and 35-50% v / v methanol in sequence, collect the eluate obtained by eluting with 35-50% v / v methanol, and concentrate to obtain a crude extract containing the above-mentioned methyl chromone compound.
3. The method for preparing the methyl chromone compound according to claim 2, It is characterized in that In step B, the amount of the eluent is 5 column volumes; and / or In step C, the amount of the eluent is 5 column volumes; and / or In step D, the amount of the eluent used is 5 column volumes.
4. The method for preparing the methyl chromone compound according to claim 2, It is characterized in that In step B, the macroporous resin in the macroporous resin column is AB-8 resin.
5. The method for preparing the methyl chromone compound according to any one of claims 2 to 4, It is characterized in that The preparation method also includes dissolving the crude extract in a methanol aqueous solution, separating by semi-preparative high performance liquid chromatography, wherein the mobile phase is a 5% to 95% v / v acetonitrile aqueous solution-0 to 0.5% v / v formic acid aqueous solution in a volume ratio of 1.5:8.5, and isocratic elution.
6. The method for preparing the methyl chromone compound according to claim 5, It is characterized in that The chromatographic column of the semi-preparative high performance liquid chromatography is octadecyl bonded silica gel; and / or The column temperature of the semi-preparative HPLC method is 25-35°C; and / or The flow rate of the semi-preparative high performance liquid chromatography is 1.5 to 2.5 mL / min.
7. The method for preparing the methyl chromone compound according to claim 6, It is characterized in that The chromatographic column of the semi-preparative HPLC method is YMC-Pack R&D ODS-A, with specifications of 250×20 mm, S-10 μm; The column temperature of the semi-preparative HPLC method is 30°C; and / or The flow rate of the semi-preparative HPLC was 2 mL / min.
8. Use of the methyl chromone compound according to claim 1 in the preparation of 3CL hydrolase inhibitors.
9. Use of the methyl chromone compound according to claim 1 in the preparation of anti-coronavirus drugs.
10. The use according to claim 9, It is characterized in that The anti-coronavirus drug is an anti-severe acute respiratory syndrome coronavirus type 2 virus drug.
